ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
AnaptysBio Inc

AnaptysBio Inc (ANAB)

38.48
0.95
(2.53%)
Closed September 22 4:00PM
38.48
-0.02
(-0.05%)
After Hours: 6:55PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
38.48
Bid
31.00
Ask
41.37
Volume
513,259
37.10 Day's Range 39.115
13.36 52 Week Range 41.3083
Market Cap
Previous Close
37.53
Open
37.60
Last Trade
317
@
38.48
Last Trade Time
Financial Volume
$ 19,517,431
VWAP
38.0265
Average Volume (3m)
319,067
Shares Outstanding
30,184,531
Dividend Yield
-
PE Ratio
-7.10
Earnings Per Share (EPS)
-5.42
Revenue
17.16M
Net Profit
-163.62M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was $37.53. Over the last year, AnaptysBio shares have traded in a share price range of $ 13.36 to $ 41.3083.

AnaptysBio currently has 30,184,531 shares outstanding. The market capitalization of AnaptysBio is $1.13 billion. AnaptysBio has a price to earnings ratio (PE ratio) of -7.10.

AnaptysBio (ANAB) Options Flow Summary

Overall Flow

Bearish

Net Premium

-25k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ANAB Latest News

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.48-1.2320328542138.9640.736.534027438.5233945CS
40.972.5859770727837.5140.734.376925677637.48921557CS
1213.4853.922541.308323.7231906734.07358366CS
2615.4567.086409031723.0341.308318.4934675227.71249866CS
5219.95107.66324878618.5341.308313.3630460724.61933046CS
15611.8644.552967693526.6241.308313.3626289424.52961753CS
260-2.57-6.2606577344741.0542.39.1633274321.84425222CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BNZIBanzai International Inc
$ 5.645
(96.01%)
61.39M
ZJYLJin Medical International Ltd
$ 3.975
(50.00%)
1.24M
ANEBAnebulo Pharmaceuticals Inc
$ 2.9001
(39.43%)
78.85k
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
AENTAlliance Entertainment Holding Corporation
$ 2.74
(34.31%)
4.23M
GSIWGarden Stage Ltd
$ 1.34
(-82.89%)
26.44M
CRBPCorbus Pharmaceuticals Holdings Inc
$ 19.51
(-62.26%)
12.29M
LGCBLinkage Global Inc
$ 0.4183
(-57.70%)
2.16M
BFIBurgerFi International Inc
$ 0.0855
(-42.27%)
15.05M
SKYESkye Bioscience Inc
$ 3.17
(-42.26%)
5.14M
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
NVDANVIDIA Corporation
$ 116.00
(-1.59%)
378.16M
AAPLApple Inc
$ 228.20
(-0.29%)
320.24M
INTCIntel Corporation
$ 21.84
(3.31%)
261.68M
VERBVerb Technology Company Inc
$ 0.0742
(33.45%)
178.65M

ANAB Discussion

View Posts
Monksdream Monksdream 1 week ago
ANAB definite uptrend
πŸ‘οΈ0
gfp927z gfp927z 2 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
πŸ‘οΈ0
HighPeaks HighPeaks 2 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
πŸ‘οΈ0
tedpeele tedpeele 2 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
πŸ‘οΈ0
HighPeaks HighPeaks 2 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
πŸ‘οΈ0
TFMG TFMG 4 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


πŸ‘οΈ0
LoveItInBishop LoveItInBishop 5 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
waterchaser waterchaser 5 years ago
LOL! Twitter PnD. Buyer beware.
πŸ‘οΈ0
420man 420man 5 years ago
Once the real bounce starts it will be fast....
πŸ‘οΈ0
Crazy Money Crazy Money 5 years ago
$10 to da moon
πŸ‘οΈ0
420man 420man 5 years ago
This will bounce..... 15 AH
πŸ‘οΈ0
RJ Trotts RJ Trotts 5 years ago
trying to bounce back over $11, hoping for more
πŸ‘οΈ0
TaxiCaT TaxiCaT 5 years ago
Ouch -
πŸ‘οΈ0
celle celle 5 years ago
Nothing happen here?
πŸ‘οΈ0
manny371 manny371 7 years ago
This stock is making noise! Bought in Sept $ANAB
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock